GSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:

Size: px
Start display at page:

Download "GSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: Rotarix TM (HRV): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus (HRV) vaccine. Study No.: (EPI-ROTA ) Title: Case-control study to evaluate the vaccine effectiveness of Rotarix TM against rotavirus severe gastroenteritis (RV SGE) among hospitalized children born after 6 March 2006 and at least 12 weeks of age, in Belem, Brazil. Rationale: To evaluate the vaccine effectiveness (VE) of HRV full series (2 doses) vaccination in preventing rotavirus (RV) severe gastroenteritis (SGE) hospitalizations among infants in Brazil. The study was conducted in 2 parts: a Case-Control Part (for a period of 12 months from the date of study initiation) and a RV Strain Surveillance Part (for a period of 36 months from the date of study initiation), which was conducted for the hospitalized subjects enrolled and for whom stool samples were tested positive for RV. Study Period: 14-May-2008 to 11-May-2011 Objectives: Primary objective To estimate the effectiveness of HRV full series (2 doses) vaccination in preventing RV SGE among children hospitalized at four clinics/hospitals in Belem area, who were born after 6 March 2006 and were at least 12 weeks of age. Secondary objectives To estimate the proportion of SGE among all clinic/hospital admissions in children born after 6 March 2006 and at least 12 weeks of age. To estimate the proportion of all RV SGE admissions in children born after 6 March 2006 and at least 12 weeks of age. To determine the distribution of RV SGE clinics/hospitals admissions by the age of the child and month of year. To determine the RV serotypes causing RV SGE among hospitalized children born after 6 March 2006 and at least 12 weeks of age. To estimate the effectiveness of HRV vaccine in preventing RV SGE hospitalization in children born after 6 March 2006 and at least 12 weeks of age, when used in typical real life situations (i.e. 1 or 2 doses). Indication: Prevention of RV SGE in infants aged at least 12 weeks. Study Investigators/Centers: GSK conducted study, 4 centers in Brazil. Research Methods: Data Source: Parents/guardians interview, review of medical records and vaccination cards, stool sampling Study Design: A hospital-based, multi-centered, matched case-control study. Study Population: Cases: Male or female children born after 6 March 2006 and at least 12 weeks of age, admitted to the study clinics/hospitals for SGE during the study period with onset of SGE 14 days prior to admission, whose stool samples tested positive (by Enzyme-Linked Immunosorbent Assay [ELISA]) for RV at hospital admission or during the first 48 hours of hospitalization. Controls: Children born within 6 weeks (maximum) from the date of birth of the case, admitted for non-gastroenteritis (GE) causes at the same clinic/hospital as the case were included in the study as hospital controls. Children born within 8 weeks from the date of birth of the case, living in the same neighborhood as the case for at least 3 consecutive months without any GE or SGE symptoms were included in the study as neighborhood controls. For all the subjects, written informed consent was obtained from the subjects parents or guardians. Study Exposures, Outcomes: The study groups were as follows: : included subjects hospitalized for SGE and tested positive for RV. Hos-con (Hospitalized controls) Group: included subjects hospitalized for non-ge causes in the same hospital as the case Nei-con (Neighborhood controls) Group: included subjects residing in the same area as the case at least for 3 consecutive months, without any symptoms of GE or SGE Primary outcome:

2 Risk of ELISA-confirmed RV SGE in children fully vaccinated with HRV vaccine (born after 6 March 2006 and at least 12 weeks of age), compared to risk of ELISA-confirmed RV SGE in children (born after 6 March 2006 and at least 12 weeks of age). Secondary outcome(s): Risk of ELISA-confirmed RV SGE in children vaccinated with at least one dose of HRV vaccine (born after 6 March 2006 and at least 12 weeks of age), compared to risk of ELISA-confirmed RV SGE in children (born after 6 March 2006 and at least 12 weeks of age). Occurrence of SGE among children born after 6 March 2006 and at least 12 weeks of age and admitted to study clinics/hospitals for SGE. Occurrence of RV genotypes among children born after 6 March 2006 and at least 12 weeks of age. Data Analysis Methods: The analyses were performed on the Screened cohort, the Total enrolled cohort, the According To Protocol (ATP) cohort, the ATP cohort for and matched neighborhood controls and the ATP cohort for and matched hospital controls: - The Screened cohort included all children born after 6 March 2006 and at least 12 weeks of age who were admitted to the hospital for symptoms of SGE. - The Total enrolled cohort included all children ( and controls) enrolled into the study. - The ATP cohort included all children ( and controls) who were enrolled into the surveillance until the study end, meeting all inclusion/exclusion criteria and complying with the study procedures. - The ATP cohort for and matched neighborhood controls included all valid and their matched neighborhood controls (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol). - The ATP cohort for and matched hospital controls included all valid and their matched hospital controls (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol). Primary objective: The VE (estimated as 1 minus the matched odds ratio multiplied by 100%) of full vaccination series of HRV vaccine in preventing RV SGE associated hospital admissions for against matched neighborhood controls and matched hospital controls was calculated using 95% Confidence Interval (CI) for the Case Control Part. Only who received HRV vaccine at least 14 days before the onset of SGE were considered as vaccinated for analysis purposes. Secondary objectives: The following analyses were performed for the Case-Control Part and/ or the RV Strain surveillance Part : - The proportion of all hospital admissions caused by SGE was calculated, with its 95% confidence interval (CI), as the total number of SGE hospitalizations out of total number of hospitalizations. - The proportion of SGE hospitalizations among children attributable to RV was calculated, with its, as the total number of confirmed RV SGE hospitalizations out of total number of SGE hospitalizations. - The percentage of RVSGE hospitalizations by age groups and RVSGE seasonal distribution by month of a year and by month and age group were tabulated.by - The VE of partial vaccination series was calculated as the VE for the full vaccination series. - The distribution of RV genotypes was also tabulated. Limitations: Not applicable. Study Results: Demographics/Baseline Characteristics Case-Control Part Hos-con Group Nei-con Group Planned, N N (Total enrolled cohort) Females: Males 265: : :190 Mean Age, months (SD) 16.9 (6.98) 18.3 (7.35) 17.5 (7.04) Demographics/Baseline Characteristics Strain Surveillance Part Planned, N* 230 N (Total enrolled cohort) 1078 Females: Males 509:569 Mean Age, months (SD) 18.5 (9.38) *Planned number of for the Case Control part of the study Primary Outcome Measure: Effectiveness of HRV vaccine full series vaccination ( against neighborhood control) (ATP cohort for and matched neighborhood controls) Case-Control Part VE (in %) LL UL Sens. + Sens. -

3 fully HRV vaccine fully HRV vaccine Neicon Group Nei-con Group = 95% confidence interval; LL= lower limit, UL= upper limit Sens. + = and controls with other or unknown Rotavirus vaccination status are assumed respectively and vaccinated Sens. - = and controls with other or unknown Rotavirus vaccination status are assumed respectively vaccinated and Primary Outcome Measure: Effectiveness of HRV vaccine full series vaccination ( against hospital controls) (ATP cohort for and matched hospital controls) Case-Control Part fully HRV vaccine fully HRV vaccine Hoscon Group Hos-con Group VE (in %) LL UL Sens. + Sens = 95% confidence interval; LL= lower limit, UL= upper limit Sens. + = and controls with other or unknown Rotavirus vaccination status are assumed respectively and vaccinated Sens. - = and controls with other or unknown Rotavirus vaccination status are assumed respectively vaccinated and Secondary Outcome Measure: Effectiveness of HRV vaccine partial or full series vaccination ( against neighborhood controls) (ATP cohort for and matched neighborhood controls) Case-Control Part partial or full HRV vaccine partial or full HRV vaccine Nei-con Group Nei-con Group VE (in %) LL UL Sens. + Sens = 95% confidence interval; LL= lower limit, UL= upper limit Sens. + = and controls with other or unknown Rotavirus vaccination status were assumed respectively and vaccinated Sens. - = and controls with other or unknown Rotavirus vaccination status were assumed respectively vaccinated and Secondary Outcome Measure: Effectiveness of HRV vaccine partial or full series vaccination ( against hospital controls) (ATP cohort for and matched hospital controls) Case-Control Part partial or full HRV vaccine partial or full HRV Hos-con Group Hos-con Group VE (in %) LL UL Sens. + Sens = 95% confidence interval; LL= lower limit, UL= upper limit Sens. + = and controls with other or unknown Rotavirus vaccination status were assumed respectively and vaccinated Sens. - = and controls with other or unknown Rotavirus vaccination status were assumed respectively vaccinated and Secondary Outcome Measure: Proportion of hospitalizations attributable to SGE (Screened cohort) Case-Control Part SGE hospitalizations hospitalizations Proportion (in %) LL UL = 95% confidence interval; LL= lower limit, UL= upper limit Secondary Outcome Measure: Proportion of SGE hospitalizations attributable to RV (Screened cohort) Case-Control Part RV SGE hospitalizations SGE hospitalizations Proportion (in %) LL UL

4 = 95% confidence interval; LL= lower limit, UL= upper limit Secondary Outcome Measure: Distribution of RV serotypes (G-type) (ATP Cohort) Case-Control Part N = 538 Characteristics Categories n % LL UL Serotype G G G G G G1 G Untypeable N = number of RV SGE subjects % = n/n x 100 = 95% confidence interval; LL= lower limit, UL= upper limit Secondary Outcome Measure: Distribution of RV genotypes (P-type) (ATP Cohort) Case-Control Part N = 538 Characteristics Categories n % LL UL Genotype P[4] P[6] P[8] P[4] P[6] P[4] P[8] P[6] P[8] P[4] P[6] P[8] Untypeable N = number of RV SGE subjects % = n/n x 100 = 95% confidence interval; LL= lower limit, UL= upper limit Secondary Outcome Measure: Distribution of RV genotypes (G&P-type) (ATP cohort) Case-Control Part N = 538 Characteristics Categories n % LL UL Genotype G1 P[6] G1 P[8] G2 P[4] G2 P[6] G9 P[4] G9 P[6] G9 P[8] G12 P[6] G1-Mixed G2-Mixed G4-Mixed G12-Mixed G2-UNTYP Mixed-P[4] Mixed-P[8] Mixed-Mixed

5 UNTYP-P[6] UNTYP-Mixed UNTYP-UNTYP N = number of RV SGE subjects % = n/n x 100 = 95% confidence interval; LL= lower limit, UL= upper limit Mixed = Mixed sero or geno types Mixed-Mixed = both mixed sero and geno types UNTYP = Untypeable UNTYP-UNTYP = Untypeable of both sero and geno type Secondary Outcome Measure: Seasonal distribution of RV SGE by month and age group (ATP Cohort) Case- Control Part Month and Year Age group (months) SGE tested for RV* MAY Others 1 JUN Others 1 JUL Others 1 AUG Others 4 SEP Others 2 OCT Others 2 NOV DEC Others 3 JAN

6 Others 4 FEB Others 5 MAR Others 2 APR MAY Others 1 *From the SGE logbook Secondary Outcome Measure: Proportion of hospitalizations attributable to SGE (Screened cohort) Strain Surveillance Part SGE hospitalizations (n) hospitalizations (N) Proportion (in %) LL UL % = n/ subjects with available results x 100 LL, UL = 95% Lower and Upper exact confidence limits Secondary Outcome Measure: Proportion of SGE hospitalizations attributable to RV (Screened cohort) Strain Surveillance Part RV SGE hospitalizations (n) SGE hospitalizations (N) Proportion (in %) LL UL % = n/ subjects with available results x 100 = 95% confidence interval; LL= lower limit, UL= upper limit Secondary Outcome Measure: hospitalizations of RV SGE by age groups (ATP cohort) Strain Surveillance Part N = 1078 Age (months) n % N = RV SGE hospitalizations n = subjects in a given category % = n/n*100 Secondary Outcome Measure: Distribution of RV serotypes (G-type) (ATP cohort) Strain Surveillance Part N = 1076 Characteristics Categories n % Serotype G G G

7 G G G UNTYP Others N = number of RV SGE hospitalizations that were serotyped % = n / N x 100 UNTYP = Untypeable Secondary Outcome Measure: Distribution of RV genotypes (P-type) (ATP cohort) Strain Surveillance Part N = 1076 Characteristics Categories n % Genotype P P P P UNTYP Others N = number of RV SGE hospitalizations that were serotyped % = n / N x 100 UNTYP = Untypeable Secondary Outcome Measure: Distribution of RV genotypes (G&P-type) (ATP cohort) Strain Surveillance Part N = 1076 Characteristics Categories n % Genotype G-Mixed P-Mixed G-Mixed P[4] G-Mixed P[6] G-Mixed P[8] G-Mixed UNTYP G12 P-Mixed G12 P[6] G1 P-Mixed G1 P[4] G1 P[6] G1 P[8] G1 UNTYP G2 P-Mixed G2 P[4] G2 P[6] G2 UNTYP G3 P[8] G4 P-Mixed G9 P[4] G9 P[6] G9 P[8] G9 UNTYP UNTYP P-Mixed UNTYP P[6] UNTYP UNTYP N = number of RV SGE hospitalizations that were serotyped % = n / N x 100 UNTYP = Untypeable

8 Note: G-Mixed includes more than one G types and P-Mixed includes more than one P types Secondary Outcome Measure: Seasonal distribution of RV SGE by month of a year (ATP cohort*) Strain Surveillance Part Month & Year of RV+ (n) SGE hospitalizations % of RV+ hospitalization tested for RV (N) MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY *From the SGE logbook % = n/n x 100 Conclusion: The VE of HRV vaccine in preventing RV SGE associated hospital admissions was 75.76% for against matched neighborhood controls and 40.00% for against matched hospital controls. Date Updated: 06-September-2013

GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:

GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title: GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: 111426 (EPI-ROTA-111426) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK)

More information

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Study No.: Title: Rationale:  Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

To demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered

To demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types

Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development

More information

Rotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April

Rotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April Rotavirus serotype surveillance: Results and experiences in Tanzania Adolfine Hokororo KPA Vaccinology Symposium- 29 th April 2016 1 outline 1. Introduction-burden of RVGE 2. goals of RVGE sentinel surveillance

More information

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Seasonality of influenza activity in Hong Kong and its association with meteorological variations

Seasonality of influenza activity in Hong Kong and its association with meteorological variations Seasonality of influenza activity in Hong Kong and its association with meteorological variations Prof. Paul Chan Department of Microbiology The Chinese University of Hong Kong Mr. HY Mok Senior Scientific

More information

vaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.

vaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV Supplemental Digital Content 1. Methodology Inclusion and exclusion criteria Eligible participants were infants between and including 6 10 weeks of age at the time of the first vaccination, who were free

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office. Global and National Trends in Vaccine Preventable Diseases Dr Brenda Corcoran National Immunisation Office Global mortality 2008 Children under 5 years of age 1.5 million deaths due to vaccine preventable

More information

For the additional vaccination phase

For the additional vaccination phase The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source: GSK Medicine: Not applicable Study No.: 113564 (EPI-HAV-003 BOD MX) Title: Sero-prevalence of Hepatitis A, Varicella-Zoster virus, Cytomegalovirus, Herpes Simplex and Bordetella pertussis in Mexico. Rationale:

More information

Bangladesh: How to move from data to implementation. K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b

Bangladesh: How to move from data to implementation. K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b Bangladesh: How to move from data to implementation K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b Rotavirus in Bangladesh Estimated 2.4 million cases of rotavirus diarrhoea annually in

More information

Long-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008

Long-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases

Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases TECHNICAL DOCUMENT Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Effectiveness

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations

Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,

More information

Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.

More information

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Analysis of immunogenicity

Analysis of immunogenicity The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Dr. Bernd Benninghoff GSK Vaccines, GML Global Medical Affairs Director

Dr. Bernd Benninghoff GSK Vaccines, GML Global Medical Affairs Director ROTARIX the human rotavirus vaccine: -is applied in a 2-dose schedulecompletes the course at the earliest possible age, prevents morbidity and mortality from RV GE regardless of the circulating strains

More information

GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:

GSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

McLean ebasis plus TM

McLean ebasis plus TM McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797

More information

Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.

subjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

California 2010 Pertussis Epidemic. Kathleen Winter, MPH Immunization Branch California Department of Public Health

California 2010 Pertussis Epidemic. Kathleen Winter, MPH Immunization Branch California Department of Public Health California 2010 Pertussis Epidemic Kathleen Winter, MPH Immunization Branch California Department of Public Health Overview Pertussis Background California Pertussis Epidemic Challenges and Success Ongoing

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Prevention of Rotavirus Infections. Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti

Prevention of Rotavirus Infections. Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti Prevention of Rotavirus Infections Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti Worldwide, Rotavirus Accounted for ~215,000 Childhood Deaths Annually 1 (2000-2013) In children less than 5 years of age:

More information

Durham Region Influenza Bulletin: 2017/18 Influenza Season

Durham Region Influenza Bulletin: 2017/18 Influenza Season Durham Region Influenza Bulletin: 2017/18 Influenza Season Surveillance Week 21 (May 20, 2018 to May 26, 2018) Table 1: Assessment of influenza activity in Durham Region Measure Laboratory confirmed cases

More information

Breast Test Wales Screening Division Public Health Wales

Breast Test Wales Screening Division Public Health Wales Breast Test Wales Screening Division Public Health Wales Programme Level Agreement with Welsh Government Quarterly Report October - December Breast Test Wales - Quarterly Report October - December Service

More information

Influenza A (H1N1)pdm09 in Minnesota Epidemiology

Influenza A (H1N1)pdm09 in Minnesota Epidemiology Influenza A (H1N1)pdm09 in Minnesota Epidemiology Infectious Disease Epidemiology, Prevention and Control Division PO Box 64975 St. Paul, MN 55164-0975 Number of Influenza Hospitalizations by Influenza

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Hand, Foot, and Mouth Disease Situation Update. Hand, Foot, and Mouth Disease surveillance summary

Hand, Foot, and Mouth Disease Situation Update. Hand, Foot, and Mouth Disease surveillance summary Hand, Foot, and Mouth Disease Situation Update 24 February 215 Hand, Foot, and Mouth Disease surveillance summary This surveillance summary includes information from countries where transmission of Hand,

More information

HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE

HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE HIV POSITIVE YOUTH: LINKAGE & RETENTION IN CARE Site C Youth clinic HIV care pathway DAY 1 Test HIV + PIMA point of care CD4 count in in 3-5 days initiation + in session 3 session 4 1 month Youth Club

More information

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016 Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events September 13, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient

More information

Influenza Season, Boston

Influenza Season, Boston 2016-2017 Influenza Season, Boston Infectious Disease Bureau Boston Public Health Commission Boston Public Health Commission Influenza Surveillance: Boston, 2016-2017 Influenza cases diagnosed in Boston

More information

Community and Hospital Surveillance

Community and Hospital Surveillance 6SSN 2324-497 Community and Hospital Surveillance ILI, SARI, Influenza and Respiratory Pathogens 217 Influenza Season, Week 3, ending 3 July 217 SUMMARY Influenza-like illness (ILI) consultation rates

More information

How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries?

How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries? How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries? Elmira Flem Department of Vaccines Norwegian Institute of Public Health Nordic Vaccine Meeting April

More information

Core 3: Epidemiology and Risk Analysis

Core 3: Epidemiology and Risk Analysis Core 3: Epidemiology and Risk Analysis Aron J. Hall, DVM, MSPH, DACVPM CDC Viral Gastroenteritis Team NoroCORE Full Collaborative Meeting, Atlanta, GA November 7, 2012 Core 3: Purpose and Personnel * Purpose:

More information

GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert

GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix Method of administration Rotarix is for oral use only. ROTARIX SHOULD UNDER NO

More information

MenC. MenW MenY

MenC. MenW MenY The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

A Human Rotavirus Vaccine

A Human Rotavirus Vaccine 7th International Rotavirus Symposium Lisbon, Portugal, 12-13 June 2006 A Human Rotavirus Vaccine Dr. Béatrice De Vos GlaxoSmithKline Biologicals Rixensart, Belgium Rotarix is a trade mark of the GlaxoSmithKline

More information

TB Outbreak in a Homeless Shelter

TB Outbreak in a Homeless Shelter TB Outbreak in a Homeless Shelter Objectives Epidemiology of Outbreak Population Health Interventions Population Health Goals 2007 One active case identified Less than compliant Prolonged recovery Contact

More information

Influenza Season, Boston

Influenza Season, Boston 2017-2018 Influenza Season, Boston Infectious Disease Bureau SLIDE 1 Influenza Surveillance, Boston, 2017-2018 The 2017-2018 influenza season refers to the period between 10/1/2017-5/5/2018. Influenza

More information

Assessing Change with IIS. Steve Robison Oregon Immunization Program

Assessing Change with IIS. Steve Robison Oregon Immunization Program Assessing Change with IIS Steve Robison Oregon Immunization Program Assessing Change with IIS Steve Robison Oregon Immunization Program Overview IIS Use in Public Health Static vs Dynamic Assessment Working

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Review of Influenza Activity in San Diego County

Review of Influenza Activity in San Diego County 2015 Kick the Flu Summit Review of Influenza Activity in San Diego County 2014-2015 Season Jeffrey Johnson, MPH Senior Epidemiologist Epidemiology & Immunization Services Branch Public Health Services

More information

Influenza Season, Boston

Influenza Season, Boston 2014-2015 Influenza Season, Boston Infectious Disease Bureau Boston Public Health Commission Influenza Surveillance: Boston, 2014-2015 Influenza cases diagnosed in Boston and confirmed by any laboratory

More information

New Brunswick Influenza Activity Summary Report: season (Data from August 30,2015 to June 4,2016)

New Brunswick Influenza Activity Summary Report: season (Data from August 30,2015 to June 4,2016) New Brunswick Influenza ctivity Summary Report: - season (Data from ugust 30, to June 4,) Highlights of the - Influenza season: This season, we experienced later influenza activity than expected. This

More information

DESCRIPTION OF STUDIES AND RISK OF BIAS ASSESSMENT FOR RCTS

DESCRIPTION OF STUDIES AND RISK OF BIAS ASSESSMENT FOR RCTS DESCRIPTION OF STUDIES AND RISK OF BIAS ASSESSMENT FOR RCTS ROTAVIRUS VACCINES SCHEDULES: A SYSTEMATIC REVIEW OF SAFETY AND EFFICACY FROM RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES OF CHILDHOOD

More information

Quit Rates of New York State Smokers

Quit Rates of New York State Smokers Quit Rates of New York State Smokers Sara M. Abrams, MPH Data Manager NYS Smokers Quitline Sara.Abrams@roswellpark.org September 6, 20 Presentation Outline Basic Quitline Service How Quit Rates are defined

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Weekly Influenza News 2016/17 Season. Communicable Disease Surveillance Unit. Summary of Influenza Activity in Toronto for Week 43

Weekly Influenza News 2016/17 Season. Communicable Disease Surveillance Unit. Summary of Influenza Activity in Toronto for Week 43 + Weekly / Influenza News Week 43 (October 23 to October 29, 2016) Summary of Influenza Activity in Toronto for Week 43 Indicator (Click on the indicator Activity Level * Description name for more details)

More information

Vaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA

Vaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children

More information

Influenza Season, Boston

Influenza Season, Boston 2015-2016 Influenza Season, Boston Infectious Disease Bureau Boston Public Health Commission Boston Public Health Commission Influenza Surveillance: Boston, 2015-2016 Influenza cases diagnosed in Boston

More information

Adult Immunizations. Business Health Care Group (BHCG) April 25, Cathy Edwards. Immunization Program Advisor

Adult Immunizations. Business Health Care Group (BHCG) April 25, Cathy Edwards. Immunization Program Advisor Adult Immunizations Business Health Care Group (BHCG) April 25, 2012 Cathy Edwards Immunization Program Advisor Wisconsin Department of Health Services Division of Public Health 1 Adult Immunizations WHY

More information

An Updated Approach to Colon Cancer Screening and Prevention

An Updated Approach to Colon Cancer Screening and Prevention An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention

More information

Community and Hospital Surveillance

Community and Hospital Surveillance ISSN 2324-497 Community and Hospital Surveillance ILI, SARI, Influenza and Respiratory Pathogens 15 Influenza Season, Week 27, ending 5 July 15 SUMMARY During week 27 (29 June 5 July 15), influenza activity

More information

Dry Needling (DN) Registration

Dry Needling (DN) Registration Dry Needling (DN) Registration To register for any of our programs, please complete the enclosed registration form (next page) and mail of fax the form to us. Fees Cost of the DN 1-3 courses is US $895

More information

Alberta Health. Seasonal Influenza in Alberta. 2016/2017 Season. Analytics and Performance Reporting Branch

Alberta Health. Seasonal Influenza in Alberta. 2016/2017 Season. Analytics and Performance Reporting Branch Alberta Health Seasonal Influenza in Alberta 2016/2017 Season Analytics and Performance Reporting Branch September 2017 For more information contact: Analytics and Performance Reporting Branch Health Standards,

More information

Confounding in influenza VE studies in seniors, and possible solutions

Confounding in influenza VE studies in seniors, and possible solutions Confounding in influenza VE studies in seniors, and possible solutions Michael L. Jackson Group Health Research Institute 4 th December, 2012 1 Outline Focus is on non-specific outcomes (e.g. community-acquired

More information

SARI, Influenza and Respiratory Pathogens

SARI, Influenza and Respiratory Pathogens ISSN 2324-3589 Hospital Surveillance SARI, Influenza and Respiratory Pathogens Monthly Report, November 15 SUMMARY During weeks 45-48 (2 November 29 November 15), influenza activity decreased in hospital

More information

Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus

Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus Anna Lena Lopez, MD, MPH Director, Institute of Child Health and Human Development,

More information

Update on the dengue situation in the Western Pacific Region

Update on the dengue situation in the Western Pacific Region Dengue Situation Update 448 23 September 214 Update on the dengue situation in the Western Pacific Region Northern Hemisphere Japan As of September 22, Ministry of Health, Labour and Welfare (MHLW), Japan,

More information

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance 18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Communicable Disease Control and Vaccine Preventable Diseases/Update and Impact. Agenda

Communicable Disease Control and Vaccine Preventable Diseases/Update and Impact. Agenda Communicable Disease Control and Vaccine Preventable Diseases/Update and Impact Communicable Disease Control and Prevention Bureau (CDCP) Communicable Disease Epidemiology Section (CDEpi) Agenda Communicable

More information

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Chi-Square Goodness-of-Fit Test

Chi-Square Goodness-of-Fit Test STAT 250 Dr. Kari Lock Morgan Chi-Square Goodness-of-Fit Test SECTION 7.1 Testing the distribution of a single categorical variable : χ 2 goodness of fit (7.1) Multiple Categories So far, we ve learned

More information

Cost-Effectiveness of Lung Volume Reduction Surgery

Cost-Effectiveness of Lung Volume Reduction Surgery Cost-Effectiveness of Lung Volume Reduction Surgery The Health Industry Forum October 24, 2007 - Washington DC The National Emphysema Treatment Trial National Emphysema Treatment Trial (NETT) Multicenter,

More information

EPIDEMIOLOGY SURVEILLANCE REPORT NORTHEAST REGION FALL Namitha Reddy Regional Coordinator North/Central West Region NJDOH/EEOH/CDS

EPIDEMIOLOGY SURVEILLANCE REPORT NORTHEAST REGION FALL Namitha Reddy Regional Coordinator North/Central West Region NJDOH/EEOH/CDS EPIDEMIOLOGY SURVEILLANCE REPORT NORTHEAST REGION FALL 2014 Namitha Reddy Regional Coordinator North/Central West Region NJDOH/EEOH/CDS Overview Purpose/Objectives State and Regional Highlights Select

More information

HAEMOPHILUS INFLUENZAE INVASIVE DISEASE

HAEMOPHILUS INFLUENZAE INVASIVE DISEASE 23 Annual Morbidity Report HAEMOPHILUS INFLUENZAE INVASIVE DISEASE CRUDE DATA 35 Annual Incidence a LA County.37 California b. United States c.2 Age at Diagnosis Mean 4. years Median 36. years Range Birth

More information

Study No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group

Study No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Curators of the University of Missouri - Combined January 1, 2016 through December 31, 2016

Curators of the University of Missouri - Combined January 1, 2016 through December 31, 2016 Cost Management Report Delta Dental Network Coverage Network Utilization Discount Delta Dental PPO Network 28.3% 29.4% Delta Dental Premier Network 67.0% 12.0% Total 95.3% Savings Categories $ % of Net

More information